BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
VANCOUVER, British Columbia, April 25, 2017 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming 2017 Annual Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, May 2nd 2017 at 9:30 AM Eastern Time.
A live audio webcast and archive of the event will be available at: http://www.wsw.com/webcast/bloomburton/aqxp/
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. In September 2016, we began enrolling patients in a Phase 3 clinical trial of AQX-1125 in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.629.9223 Ext. 109
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
